Expression of CD23 in the germinal center of thymus from myasthenia gravis patients

Journal of Neuroimmunology

Volumn 76, Issue 1-2, 1997, Pages 61-69

  Murai, Hiroyuki ^a   Hara, Hideo ^a   Hatae, Tomoko ^a   Kobayashi, Takuro ^a   Watanabe, Takeshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

CD23; Germinal center; Myasthenia gravis; Soluble CD23; Thymus

Indexed keywords

CD23 ANTIGEN; MONOCLONAL ANTIBODY;

ADULT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GERMINAL CENTER; HUMAN; HUMAN TISSUE; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; THYMECTOMY; THYMUS HYPERPLASIA;

ANTIGENS, CD19; AUTOANTIBODIES; GERMINAL CENTER; HUMANS; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC; RECEPTORS, IGE;

EID: 0030904235     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(97)00030-1     Document Type: Article

References (40)

1. al-Janadi M., al-Wabel A., Raziuddin S. Soluble CD23 and interleukin-4 levels in autoimmune chronic active hepatitis and systemic lupus erythematosus. Clin. Immunol. Immunopathol. 71:1994;33-37.
2. Aubry J.-P., Pochon S., Graber P., Jansen K.U., Bonnefoy J.-Y. CD21 is a ligand for CD23 and regulates IgE production. Nature. 358:1992;505-507.
3. Bansal A.S., Ollier W., Marsh M.N., Pumphrey R.S.H., Wilson P.B. Variations in serum sCD23 in conditions with either enhanced humoral or cell-mediated immunity. Immunology. 79:1993;285-289.
4. Bansal A., Roberts T., Hay E.M., Kay R., Pumphrey R.S.H., Wilson P.B. Soluble CD23 levels are elevated in the serum of patients with primary Sjögren's syndrome and systemic lupus erythematosus. Clin. Exp. Immunol. 89:1992;452-455.
5. Besinger U.A., Toyka K.V., Hömberg M., Heininger K., Hohlfeld R., Fateh-Moghadam A. Myasthenia gravis: Long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology. 33:1983;1316-1321.
6. Bofill M., Janossy G., Willcox N., Chilosi M., Trejdosiewicz L.K., Newsom-Davis J. Microenvironments in the normal thymus and the thymus in myasthenia gravis. Am. J. Pathol. 119:1985;462-473.
7. Bonnefoy J.-Y., Henchoz S., Hardie D., Holder M.J., Gordon J. A subset of anti-CD21 antibodies promote the rescue of germinal center B cells from apoptosis. Eur. J. Immunol. 23:1993;969-972.
8. Chomarat P., Briolay J., Banchereau J., Miossec P. Increased production of soluble CD23 in rheumatoid arthritis, and its regulation by interleukin-4. Arthritis Rheum. 36:1993;234-242.
9. D'Andrea V., Malinovsky L., Ambrogi V., Artico M., Capuano L.G., Buccolini F., De Antoni E. Thymectomy as treatment of autoimmune diseases other than myasthenia gravis. Thymus. 21:1993;1-10.
10. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330:1994;1797-1810.
11. Facchetti F., Appiani C., Salvi L., Levy J., Notarangelo L.D. Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymphoid tissues from patients with X-linked immunodeficiency with hyper-IgM. Abortive germinal center cell reaction and severe depletion of follicular dendritic cells. J. Immunol. 154:1995;6624-6633.
12. Fischer A., König W. Regulation of CD23 expression, soluble CD23 release and immunoglobulin synthesis of peripheral blood lymphocytes by glucocorticoids. Immunology. 71:1990;473-479.
13. Fujiwara H., Kikutani H., Suematsu S., Naka T., Yoshida K., Yoshida K., Tanaka T., Suemura M., Matsumoto N., Kojima S., Kishimoto T., Yoshida N. The absence of IgE antibody-mediated augmentation of immune responses in CD23-deficient mice. Proc. Natl. Acad. Sci. USA. 91:1994;6835-6839.
14. Gonzalez-Molina A., Spiegelberg H.L. Binding of IgE myeloma proteins to human cultured lymphoblastoid cells. J. Immunol. 117:1976;1838-1845.
15. Han S., Hathcock K., Zheng B., Kepler T.B., Hodes R., Kelsoe G. Cellular interaction in germinal centers. Roles of CD40 ligand and B7-2 in established germinal centers. J. Immunol. 155:1995;556-567.
16. Hardie D.L., Johnson G.D., Khan M., MacLennan I.C.M. Quantitative analysis of molecules which distinguish functional compartments within germinal centers. Eur. J. Immunol. 23:1993;997-1004.
17. Ikizawa K., Yanagihara Y., Kajiwara K., Koshio T., Shida T., Yamada A. Possible role of CD5+ B cells expressing CD23 in mediating the elevation of serum-soluble CD23 in patients with rheumatoid arthritis. Int. Arch. Allergy Immunol. 101:1993;416-424.
18. Johnson G.D., Hardie D.L., Ling N.R., MacLennan I.C.M. Human follicular dendritic cells (FDC): A study with monoclonal antibodies (MoAb). Clin. Exp. Immunol. 64:1986;205-213.
19. Kintner C., Sugden B. Identification of antigenic determinants unique to the surfaces of cells transformed by Epstein-Barr virus. Nature. 294:1981;458-460.
20. Kornstein M.J., Brooks J.J., Anderson A.O., Levinson A.I., Lisak R.P., Zweiman B. The immunohistology of the thymus in myasthenia gravis. Am. J. Pathol. 117:1984;184-194.
21. Leprince C., Cohen-Kaminsky S., Berrih-Aknin S., Vernet-Der Garabedian B., Treton D., Galanaud P., Richard Y. Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis. J. Immunol. 145:1990;2115-2122.
22. Letellier M., Nakajima T., Pulido-Cejudo G., Hofstetter H., Delespesse G. Mechanism of formation of human IgE-binding factors (soluble CD23). III. Evidence for a receptor (FcεRII)-associated proteolytic activity. J. Exp. Med. 172:1990;693-700.
23. Letellier M., Sarfati M., Delespesse G. Mechanisms of formation of IgE-binding factors (soluble CD23)-I. FcεRII bearing B cells generate IgE-binding factors of different molecular weights. Mol. Immunol. 26:1989;1105-1112.
24. Levinson A.I., Lisak R.P., Zweiman B., Kornstein M. Phenotypic and functional analysis of lymphocytes in myasthenia gravis. Springer Semin. Immunopathol. 8:1985;209-233.
25. Lewis R.A., Selwa J.F., Lisak R.P. Myasthenia gravis: Immunological mechanisms and immunotherapy. Ann. Neurol. 37:1995;S51-S62.
26. Liu Y.-J., Cairns J.A., Holder M.J., Abbot S.D., Jansen K.U., Bonnefoy J.Y., Gordon J., MacLennan I.C.M. Recombinant 25-kDa CD23 and interleukin 1α promote the survival of germinal center B cells: Evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur. J. Immunol. 21:1991;1107-1114.
27. Liu Y.-J., Mason D.Y., Johnson G.D., Abbot S., Gregory C.D., Hardie D.L., Gordon J., MacLennan I.C.M. Germinal center cells express bcl-2 protein after activation by signals which prevent their entry into apoptosis. Eur. J. Immunol. 21:1991;1905-1910.
28. Liu Y.-J., Johnson G.D., Gordon J., MacLennan I.C.M. Germinal centres in T-cell-dependent antibody responses. Immunol. Today. 13:1992;17-21.
29. Mangeney M., Rousselet G., Taga S., Tursz T., Wiels J. The fate of human CD77+ germinal center B lymphocytes after rescue from apoptosis. Mol. Immunol. 32:1995;333-339.
30. Moulder K., Barton A., Weston B. CD23-mediated homotypic cell adhesion: The role of proteolysis. Eur. J. Immunol. 23:1993;2066-2071.
31. Newsom-Davis J., Willcox N., Calder L. Thymus cells in myasthenia gravis selectively enhance production of anti-acetylcholine-receptor antibody by autologous blood lymphocytes. N. Engl. J. Med. 305:1981;1313-1318.
32. Newsom-Davis J., Willcox N., Schluep M., Harcourt G., Vincent A., Mossman S., Wray D., Burges J. Immunological heterogeneity and cellular mechanisms in myasthenia gravis. Ann. NY Acad. Sci. 505:1987;12-26.
33. Stief A., Texido G., Sansig G., Eibel H., Le Gros G., van der Putten H. Mice deficient in CD23 reveal its modulatory role in IgE production but no role in T and B cell development. J. Immunol. 152:1994;3378-3390.
34. Sutton B.J., Gould H.J. The human IgE network. Nature. 366:1993;421-428.
35. Tedder T.F., Zhou L.-J., Engel P. The CD19/CD21 signal transduction complex of B lymphocytes. Immunol. Today. 15:1994;437-442.
36. Thomas J.A., Willcox H.N., Newsom-Davis J. Immunohistological studies of the thymus in myasthenia gravis. Correlation with clinical state and thymocyte culture responses. J. Neuroimmunol. 3:1982;319-335.
37. Weiner H.L., Hauser S.L. Neuroimmunology I: Immunoregulation in neurological disease. Ann. Neurol. 11:1982;437-449.
38. Whitaker J.N. Myasthenia gravis and autoimmunity. Adv. Intern. Med. 26:1980;489-510.
39. Xu J., Foy T.M., Laman J.D., Elliott E.A., Dunn J.J., Waldschmidt T.J., Elsemore J., Noelle R.J., Flavell R.A. Mice deficient for the CD40 ligand. Immunity. 1:1994;423-431.
40. Yukawa K., Kikutani H., Owaki H., Yamasaki K., Yokota A., Nakamura H., Barsumian E.L., Hardy R.R., Suemura M., Kishimoto T. A B cell-specific differentiation antigen, CD23, is a receptor for IgE (FcεR) on lymphocytes. J. Immunol. 138:1987;2576-2580.